Activated protein C (APC) resistance (Dahlbäck *et al*, [@b8]) is a common risk factor for venous thromboembolism (Bucciarelli *et al*, [@b4]). This phenotype is highly associated with the *F5* R506Q (*F5* rs6025; factor V Leiden, FVL) mutation (Bertina *et al*, [@b2]). Heterozygous and homozygous discrepancies between *F5* R506Q genotype and phenotype (APC resistance), known as pseudo-homozygosity, have been described (Castaman *et al*, [@b5]; Brugge *et al*, [@b3]). This incidental phenomenon suggests that, based on APC-resistance testing, there is a homozygous *F5* R506Q mutation, yet, genetic testing only shows a heterozygous *F5* R506Q mutation (Simioni *et al*, [@b10]). In such cases, polymorphisms located on the second factor V (FV) protein coding allele (i.e. wild-type for *F5* R506Q) cause intracellular decreased FV protein production, leading to reduced FV activity (Castoldi *et al*, [@b6]). In contrast, the phenomenon "pseudo-wild-type" FVL, suggesting a wild-type *F5* R506Q according to APC resistance testing but heterozygous *F5* R506Q mutation by genetic testing, is infrequently described (Dargaud *et al*, [@b9]; Asselta *et al*, [@b1]). In these two studies, the polymorphisms responsible for the reduced FV protein levels were found to be located on the same FV protein coding allele, together with the *F5* R506Q mutation.

In this study, four cases with such a "pseudo-wild-type" FVL, based on a novel detected polymorphism, were investigated. An adolescent, healthy female subject was advised by her physician to determine her *F5* R506Q status before being prescribed hormonal contraceptives. She was a non-smoker with no personal or family history of any thromboembolic events. She was tested for both APC resistance and the *F5* R506Q mutation. Because there was a discrepancy between the functional APC resistance testing and the genetic *F5* R506Q testing results, her family was tested and a pedigree was established. (Supporting Information [Data S1](#SD1){ref-type="supplementary-material"}) In the index subject, a heterozygous *F5* R506Q mutation but a normal APC ratio were detected (Fig [1](#fig01){ref-type="fig"}). The APC ratio was cross-checked using three different assays based on different FV activation pathways, which yielded consistent, normal results (Table [I](#tblI){ref-type="table"}). When the *F5* gene was sequenced in the index subject with the heterozygous *F5* R506Q mutation, a novel heterozygous missense mutation 5326G\>A (G1718S) in exon 16 of *F5* was detected ([Fig S1](#SD1){ref-type="supplementary-material"}). This novel mutation (*F5* G1718S) was registered as "factor V Graz" (FV Graz, GenBank accession number JF816043). Sequence analysis of *F5* G1718S in the PolyPhen-2 databank yielded in a "probably damaging" result \[score 1·0\] (Fig [2](#fig02){ref-type="fig"}A-c, B). The FV activity (FV:Act) and the FV antigen (FV:Ag) levels of the index subject were significantly lower when compared to the mean values of the four non-FVL family members (65% vs. 125%, *P* = 0·023; and 43% vs. 103%, *P* = 0·008; respectively).

###### 

Activated protein C (APC) ratios in the plasma of all family members using three different test systems \[Pefakit® APC Resistance (APC-R) Factor V Leiden assay, HEMOCLOT® Quanti V-L and COATEST® APC™ Resistance\] in comparison with the *F5* genotypes \[*F5* R506Q (FV Leiden) and *F5* G1718S (FV Graz)\]

  Family member                  *F5* R506Q (Factor V Leiden)   *F5* G1718S (Factor V Graz)   Pefakit® \[ratio\]   HEMOCLOT® \[%\]   COATEST® \[ratio\]
  ------------------------------ ------------------------------ ----------------------------- -------------------- ----------------- --------------------
  Cut off                                                                                     \>2·9                \<10              \>2·2
  I.1                            HE                             HE                            3·03                 7·95              2·34
  I.2                            WT                             WT                            4·20                 3·15              2·87
  I.3                            WT                             WT                            4·00                 2·15              2·83
  I.4                            WT                             WT                            4·36                 2·30              2·50
  II.1                           HE                             HE                            3·09                 7·35              2·39
  II.2                           WT                             WT                            4·20                 2·95              3·00
  INDEX III.1                    HE                             HE                            3·30                 6·63              2·42
  III.2                          HE                             HE                            3·13                 7·45              2·52
  Controls *F5* R506Q carriers   HE                             WT                            1·4--2·5             14--86            1·3--2·2

HE, heterozygous; WT, wild-type.

![The INDEX subject is indicated by the arrow. Half-filled symbols denote carriers of the heterozygous *F5* R506Q (factor V Leiden) mutation and the novel heterozygous missense mutation *F5* G1718S (factor V Graz). Double heterozygosity for *F5* R506Q and *F5* G1718S is associated with a normal activated protein C ratio (APCR), low FV activity (FV:Act %) and low FV antigen (FV:Ag %). The mean FV:Act and FV:Ag values in the double heterozygous carriers for *F5* R506Q and *F5* G1718S were significantly lower than in wild-type carriers (67% vs. 125%, *P* \< 0·005 and 40% vs. 103%, *P* \< 0·001, respectively).](bjh0163-0414-f1){#fig01}

![(A, B) Co-inheritance of heterozygous factor V Leiden mutation (*F5* 1691G\>A, *F5* R506Q) and heterozygous factor V Graz (*F5* 5326G\>A, *F5* G1718S): The factor V Graz mutation is located in the A3 domain of the coagulation factor V; Mutations between the amino acid positions 1608 to 1745 are responsible for a premature factor V protein degradation and lead to the expression of a reduced amount of factor V protein (B). (a) Inheritance of heterozygous *F5* R506Q mutation, leading to a normal amount of factor V protein; half of the protein is resistant to activated protein C ( = APC resistance present). (b) The co-inheritance of *F5* R506Q mutation and the *F5* G17181S mutation on different alleles results in the expression of the FV Leiden protein only ( = pseudo-homozygous APC resistance). (c) In the studied family, the co-inheritance of the *F5* G17181S mutation and *F5* R506Q mutation on the same allele leads to the expression of the non-FV Leiden protein only, resulting in a normal APC ratio ( = "pseudo-wild-type" APC resistance).](bjh0163-0414-f2){#fig02}

Her brother, mother, and maternal grandmother were found to be double heterozygous for *F5* R506Q and *F5* G1718S, and have a normal APC ratio. In these subjects the FV:Act and FV:Ag were also significantly lower when compared to those of the non-*F5* R506Q/non-*F5* G1718S family members (Fig [1](#fig01){ref-type="fig"}).

Her father, paternal grandparents and maternal grandfather were each found to be wild-type for *F5* R506Q and *F5* G1718S, and have normal APC ratio, FV:Act and FV:Ag (Fig [1](#fig01){ref-type="fig"}).

In the investigated family, three female subjects and one male subject showed a discrepancy between genotype and phenotype: a heterozygous *F5* R506Q mutation but normal APC ratios, which was caused by a novel sequenced mutation (*F5* G1718S). Interestingly, this novel *F5* G1718S mutation is located on the same allele as the heterozygous *F5* R506Q mutation. Therefore, we hypothesized that this new *F5* G1718S mutation is responsible for the low FV:Ag level. In this case, only a reduced amount of normal FV, which is coded by the second unaffected allele, is available and accounts for a wild-type-like normal APC ratio, suggesting a "pseudo-wild-type" for the *F5* R506Q mutation (Fig [2](#fig02){ref-type="fig"}A-c).

This infrequent phenomenon (Dargaud *et al*, [@b9]; Asselta *et al*, [@b1]) was explained by a missense or a frameshift mutation on the *F5* gene, which causes amino acids to be exchanged or prematurely terminated, resulting in reduced FV protein levels. Published exchanges of amino acids in the region 1608 and 1745 of the *F5* gene result in low FV protein levels (Fig [2](#fig02){ref-type="fig"}B) (Castoldi *et al*, [@b7]). Based on these findings, our novel missense mutation, detected at position 1718 of the FV protein, lies within the described region 1608 -- 1745, and therefore seems to be the reason for both the markedly reduced FV:Act and FV:Ag levels measured in our four study subjects. When comparing our findings of the "pseudo-wild-type" FVL to the well-described pseudo-homozygous FVL, the main difference exists in the location of the *F5* R506Q mutation and the additional missense mutation on the *F5* gene causing the reduced FV protein levels: For "pseudo-wild-type" FVL, both mutations have to be located on the same FV protein coding allele; whereas, for pseudo-homozygous FVL, the mutations have to be located on the different FV protein coding alleles, as demonstrated (Fig [2](#fig02){ref-type="fig"}A, [Table S1](#SD1){ref-type="supplementary-material"}).

The medical history of the entire family was ascertained and considered when evaluating the "pseudo wild-type" FVL test results and determining the haemostasis risk burden. None of the subjects had a history of thromboembolic events or any bleeding complications. Therefore, it can be assumed that the thromboembolic risk that is usually associated with a heterozygous *F5* R506Q mutation is no longer reliable if missense mutations, e.g., the *F5* G1718S mutation, located on the same allele as the *F5* R506Q mutation, are present.

In summary, the *F5* G1718S mutation causes a normal APC ratio despite the presence of a heterozygous *F5* R506Q mutation -- described as a "pseudo-wild-type" FVL.

In these four cases, testing for only the *F5* R506Q genotype would have failed to determine the individual\'s thromboembolic risk associated with the heterozygous *F5* R506Q mutation. As numerous relevant missense mutations may exist on the *F5* gene that have not yet been detected or described, clinicians should be aware of this possible discrepancy between genetic (*F5* R506Q) and phenotypic (APC resistance) testing for FVL before drawing conclusions for thromboembolic prophylaxis and therapeutic management, especially when prescribing drugs such as combined oral contraceptives or hormonal replacement therapy.
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**Fig S1.** Detection of the novel mutation 5326G\>A (G1718S) in exon 16 of the F5 gene - Sequencing protocol and RFLP analysis of the female index patient.

**Table S1.** Phenotypic results of different co-inherited factor V Leiden heterozygous conditions in the presence of the novel heterozygous factor V Graz polymorphism and the prevalence of these conditions.

[^1]: Preliminary data were presented in part as oral presentation at the IFCC-WorldLab Berlin, May 2011.
